Literature DB >> 6212156

The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.

H C Blossey, H H Bartsch, D Kanne, J Koebberling, G A Nagel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6212156     DOI： 10.1007/bf00292875

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  26 in total

1.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Steroid structure and function--II. Conformational transmission and receptor binding of medroxyprogesterone acetate.

Authors:  W L Duax; V Cody; J Griffin; J Hazel; C M Weeks
Journal:  J Steroid Biochem       Date:  1978-10       Impact factor: 4.292

3.  Measurement of medroxyprogesterone acetate (Provera ) by radioimmunoassay.

Authors:  J C Cornette; K T Kirton; G W Duncan
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

4.  A radioimmunoassay for serum medroxyprogesterone acetate.

Authors:  K Shrimanker; B N Saxena; K Fotherby
Journal:  J Steroid Biochem       Date:  1978-04       Impact factor: 4.292

5.  In vivo metabolism of H3-medroxyprogesterone acetate in pregnant and nonpregnant women and in the fetus.

Authors:  P K Besch; N Vorys; J C Ullery; R D Barry; D Couri
Journal:  Am J Obstet Gynecol       Date:  1966-05-15       Impact factor: 8.661

6.  Biologic activity of 6-alph-amethyl compounds corresponding to progesterone, 17-alpha-hydroxyprogesterone acetate and compound S.

Authors:  E M GLENN; S L RICHARDSON; B J BOWMAN
Journal:  Metabolism       Date:  1959-05       Impact factor: 8.694

7.  Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.

Authors:  A Ortiz; M Hirol; F Z Stanczyk; U Goebelsmann; D R Mishell
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

8.  Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

Authors:  M Salimtschik; H T Mouridsen; J Loeber; E Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Isolation and identification of 6beta,17alpha,21-trihydroxy-6alpha-methyl-delta4-pregnene-3, 20-dione (21-acetate) from the urine of human subjects treated with 6alpha-methyl-17alpha-acetoxyprogesterone.

Authors:  E CASTEGNARO; G SALA
Journal:  J Endocrinol       Date:  1962-07       Impact factor: 4.286

10.  High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.

Authors:  G R Cuna; A Calciati; M R Strada; C Bumma; L Campio
Journal:  Tumori       Date:  1978-04-30
View more
  8 in total

Review 1.  Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

Authors:  A D Stockdale; A Y Rostom
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

2.  Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer.

Authors:  A A Miller; R Becher; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Medroxyprogesterone acetate does not protect human bone marrow progenitor cells exposed to adriamycin in vitro.

Authors:  G E Umbach; G Spitzer; B Drewinko; G Gercovich; G Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.

Authors:  C M Camaggi; E Strocchi; M Giovannini; B Angelelli; B Costanti; E Zebini; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  [High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles].

Authors:  H E Wander; C Blossey; J Köbberling; G A Nagel
Journal:  Klin Wochenschr       Date:  1983-06-01

6.  Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

Authors:  D W Hedley; M Christie; R P Weatherby; I D Caterson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.

Authors:  C M Camaggi; E Strocchi; B Costanti; P Beghelli; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.

Authors:  P A Canney; M Dowsett; T J Priestman
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.